Acute Effect of Photobiomodulation in Individuals with Hypertension
NCT ID: NCT06678698
Last Updated: 2024-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
48 participants
INTERVENTIONAL
2024-05-01
2025-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of Daily Ultraviolet Therapy to Reduce Cardiovascular Risk Factors
NCT02621866
Mindfulness-Based Blood Pressure Reduction (MB-BP) Intervention Development - Stage 1 Single Arm Trial
NCT02702258
A Controlled Study to Investigate the Effect of Multi-wave Light Emitting Diode (LED) Bed on Blood Pressure and Endothelial Function
NCT04006158
Smartphone App-guided Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure
NCT06229873
Efficacy of Home Blood Pressure Monitoring (MONITOR Study)
NCT00921791
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Panel Group
Participants who will receive full-body photobiomodulation irradiation, from a panel of LEDs
Panel Effective Photobiomodulation Therapy
Photobiomodulation therapy is the use of low-power light in biological tissues through a non-ionizing source of light (600 to 1.100 nm), with variable power between 1 and 500 mW and therapeutic goals.
This group will receive photobiomodulation from a whole-body panel of low intensity LEDs
Panel Sham Group
Participants who will receive full-body photobiomodulation irradiation, with the device turned-off
Sham Panel Photobiomodulation Therapy
Use of common red lamp to perform the sham photobiomodulation for the panel group
Modified ILIB Group
Participants who will receive photobiomodulation irradiation with the transcutaneous ILIB method
Modified ILIB Photobiomodulation Therapy
Common laser used in ILIB mode for modified ILIB therapy
Modified ILIB Sham Group
Participants who will received photobiomodulation irradiation with the transcutaneous ILIB method, with the device turned-off
Modified ILIB Sham Photobiomodulation Therapy
ILIB Therapy device turned off for the sham ILIB therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Panel Effective Photobiomodulation Therapy
Photobiomodulation therapy is the use of low-power light in biological tissues through a non-ionizing source of light (600 to 1.100 nm), with variable power between 1 and 500 mW and therapeutic goals.
This group will receive photobiomodulation from a whole-body panel of low intensity LEDs
Sham Panel Photobiomodulation Therapy
Use of common red lamp to perform the sham photobiomodulation for the panel group
Modified ILIB Sham Photobiomodulation Therapy
ILIB Therapy device turned off for the sham ILIB therapy
Modified ILIB Photobiomodulation Therapy
Common laser used in ILIB mode for modified ILIB therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes
* Age between 40 to 60 years old
* Clinical diagnosis of hypertension for at least 3 months with difficulty in blood pressure control
* Hypertension classification up to stage 2
* Individuals who have a prescription for hypertension control drugs and have been using these drugs for at least 3 months
Exclusion Criteria
* Smokers
* BMI \> 30 kg/m²
* Cardiac pacemaker use
* Presence of arrhythmias or other decompensated cardiovascular diseases
* Musculoskeletal, orthopedic or neurological conditions that make it unable to participate in the procedures
* Presence of cognitive deficits that make it difficult to understand the assessments
* Presence of active neoplasia, under suspicion or after 5 years in remission period
* Presence of tattoos (covering a large body area, or the anterior wrist region)
* Photosensitive drugs use
* Pregnant women or under suspicion
* Presence of epilepsy or seizures
* Participants who present a systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg on the day of the intervention
40 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundação de Amparo à Pesquisa do Estado de São Paulo
OTHER_GOV
Universidade Federal de Sao Carlos
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lara Maria Bataglia Espósito
Physical Therapist, Master's student
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Federal University of São Carlos
São Carlos, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UFSaoCarlosPBM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.